Albendazole - GSK
Alternative Names: Albenza; Bilutac®; Escazole®; Eskazole®; Proftril®; SKF 62979; Zentel®Latest Information Update: 18 Oct 2024
At a glance
- Originator GlaxoSmithKline
- Developer GSK; Neurizon Therapeutics
- Class Anthelmintics; Benzimidazoles; Carbamates; Small molecules
- Mechanism of Action Tubulin inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Helminthiasis
- Discontinued Ascites
Most Recent Events
- 15 Oct 2024 PharmAust is now called Neurizon Therapeutics
- 03 Feb 2021 Discontinued - Phase-I for Helminthiasis (In volunteers) in China (PO) (GlaxoSmithKline pipeline, February 2021)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Helminthiasis(In volunteers) in China (PO, Tablet)